Gokal R, Mallick N P
Department of Renal Medicine, Manchester Royal Infirmary, UK.
Lancet. 1999 Mar 6;353(9155):823-8. doi: 10.1016/s0140-6736(98)09410-0.
Peritoneal dialysis has now become an established form of renal replacement therapy; nearly half the patients on dialysis in the UK are treated in this way. Survival of patients is now equal to that with haemodialysis. However, long-term peritoneal dialysis (>8 years) is limited to a small percentage of patients because of dropout to haemodialysis for inherent complications of peritoneal dialysis--peritonitis, peritoneal access, inadequate dialysis, and patient-related factors. However, improvements in the understanding of the pathophysiological processes involving the peritoneal membrane have paved the way for advances in the delivery of adequate dialysis, more biocompatible dialysis fluids, and automated peritoneal dialysis. Other technical advances have led to a reduction in peritonitis. Peritoneal dialysis is an important dialysis modality and should be used as an integral part of RRT programmes.
腹膜透析现已成为一种成熟的肾脏替代治疗方式；在英国，近一半的透析患者接受这种治疗。目前患者的生存率与血液透析相当。然而，长期腹膜透析（>8年）仅限于一小部分患者，因为腹膜透析的固有并发症（腹膜炎、腹膜通路、透析不充分以及患者相关因素）导致患者转而接受血液透析。然而，对涉及腹膜的病理生理过程认识的提高为充分透析、生物相容性更好的透析液以及自动化腹膜透析的进展铺平了道路。其他技术进步也使腹膜炎的发生率有所降低。腹膜透析是一种重要的透析方式，应作为肾脏替代治疗方案的一个组成部分来使用。
